Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial
- 31 August 2005
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 27 (8), 1164-1180
- https://doi.org/10.1016/j.clinthera.2005.08.001
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers.Diabetes Care, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- A Multicenter Study on the Prevalence of Diabetic Neuropathy in ItalyDiabetes Care, 1997
- Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications StudyDiabetologia, 1996
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusThe New England Journal of Medicine, 1993
- The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohortNeurology, 1993
- A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic populationDiabetologia, 1993
- Risk Factors for Amputation in Patients with Diabetes MellitusAnnals of Internal Medicine, 1992
- Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications StudyDiabetes, 1989
- Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research GroupDiabetes, 1988